Deal to progress Alzheimer's vaccine

AFFiRiS GmbH has granted GlaxoSmithKline Biologicals S.A. (GSK) exclusive rights to develop and commercialise its Alzheimer's disease vaccine candidates. Two are currently in Phase I clinical development, and others are in preclinical development.

Photo: Deal to progress Alzheimers vaccine

The AFFiRiS AFFiTOPE technology allows the design of proteins with very specific binding characteristics that are ideally suited for the development of vaccines against disease-causing ‘rogue’ human proteins, such as beta-amyloid – central to Alzheimer’s disease pathology.
AFFiRiS GmbH (www.affiris.com) develops peptide-based vaccines to combat Alzheimer’s disease, atherosclerosis and other diseases. The company has established platform technologies and a worldwide patent portfolio covering their vaccine candidates.

20.11.2008

More on the subject:

Related articles

Photo

Article • San Antonio Breast Cancer Symposium (SABCS)

Young women and breast cancer: research in focus

At the San Antonio Breast Cancer Symposium (SABCS), three experts presented new approaches and study results for the treatment of breast cancer in young women.

Photo

News • Combining spatial transcriptomics, pseudotime and machine learning

More precise than PSA: New biomarkers for prostate cancer found in urine

Using AI and extensive analyses of gene activity in tumours, researchers have found new, precise biomarkers to diagnose prostate cancer at an early stage through a simple urine sample.

Photo

News • Targeting early versions

A 'head start' in the race against pancreatic cancer

Fighting pancreatic cancer can feel like a race against time. A new discovery could give clinicians a head start - by targeting precancerous lesions before they become much more aggressive.

Related products

Subscribe to Newsletter